A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00266240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus
Study identification
- NCT ID
- NCT00266240
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 267 participants
Conditions and interventions
Conditions
Interventions
- GK Activator (2) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- Apr 30, 2007
- Completion
- Apr 30, 2007
- Last update posted
- Nov 1, 2016
2005 – 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85723 | — |
| Not listed | Pine Bluff | Arkansas | 71603 | — |
| Not listed | Chula Vista | California | 91911 | — |
| Not listed | Spring Valley | California | 91978 | — |
| Not listed | West Hills | California | 91307 | — |
| Not listed | Hollywood | Florida | 33021 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Binghamton | New York | 13901 | — |
| Not listed | Fayetteville | North Carolina | 28304 | — |
| Not listed | Statesville | North Carolina | 28625 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Springdale | Ohio | 45246 | — |
| Not listed | Oklahoma City | Oklahoma | 73112 | — |
| Not listed | Medford | Oregon | 97504 | — |
| Not listed | Beaver | Pennsylvania | 15009 | — |
| Not listed | Tipton | Pennsylvania | 16684 | — |
| Not listed | Mt. Pleasant | South Carolina | 29464 | — |
| Not listed | Plano | Texas | 75093 | — |
| Not listed | Renton | Washington | 98055 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00266240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00266240 live on ClinicalTrials.gov.